Drugs / Inosine
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07170475 | Jun 2025 → Mar 2026 overdue | Parkinson disease | Fujita Health University | Recruiting | No outcome recorded |
| Phase 1 | NCT02614469 | Mar 2015 → Apr 2016 | — | Michael Alan Schwarzschild | Completed | No outcome recorded |
| Phase 1 | NCT02288091 | Jan 2015 → Mar 2016 | amyotrophic lateral sclerosis | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 24 trials · 1 met primary | ||||||
| Phase 2 | NCT06355024 | May 2024 → Jan 2025 | triple-negative breast carcinoma | Fudan University | Completed | No outcome recorded |
| Phase 2 | NCT03168711 | Oct 2017 → Dec 2019 | amyotrophic lateral sclerosis | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00833690 | Jun 2009 → Dec 2012 | Parkinson disease | The Parkinson Study Group | Completed | Met primary |
| Phase 2 | NCT00067327 | Feb 2002 → Sep 2005 | relapsing-remitting multiple sclerosis | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT05809336 | May 2019 → Oct 2022 | neoplasm | Beijing Friendship Hospital | Completed | Missed primary |
| Phase 32 trials · 1 met primary · 1 missed | ||||||
| Phase 3 | NCT04631484 | Nov 2020 → May 2024 | brain injury | POLYSAN Scientific & Technological Pharmaceutical Company | Completed | Met primary |
| Phase 3 | NCT02642393 | Jun 2016 → Jun 2019 | Parkinson disease | Michael Alan Schwarzschild | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| — | NCT00893724 Comparator | Jun 2009 → Aug 2011 | diabetic macular edema, wet macular degeneration | Mid-Atlantic Retina Consultations, Inc. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Inosine | “Inosine \[SR\] - 1\[500mg\] tablet bid Tocopherols \[200IU\], Tocotrienol \[10mg\], CoQ10 \[50mg\] - combination capsule bid Sustained Release Niacinamide - 1 \[750mg\] tablet...” NCT00893724 ↗ |
| Route | Oral | “daily oral administration” NCT00067327 ↗ |